標記臨床研究 XOMA 深 滬
等待開盤 12-16 09:30:00 美东时间
25.49
+0.270
+1.07%
華盛通- 最 高25.93
- 今 開25.50
- 成交量 5.83万股
- 最 低 24.96
- 昨 收 25.22
- 總市值 3.08亿
- 52周最高 39.92
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 18.352
- 委 比 77.11%
- 總股本 1208.77万
- 歷史最高 191.40
- 量 比 0.43
- 振 幅 3.85%
- 歷史最低 3.96
- 每 手 1
- 風險率 5.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多XOMA Royalty To Acquire Generation Bio Co. For A Cash Price Of $4.2913 Per Share At The Closing Of The Merger
XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of
今天 06:02
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Why Is XOMA Royalty Stock Sinking Thursday?
XOMA stock plunged after its partner Rezolute Inc. reported disappointing trial results for their product Ersodetug.
12-12 02:09
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Mural Oncology Acquisition By XOMA Royalty Subsidiary Effective December 5, Under Companies Act Scheme
Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp.
12-05 20:48
Mural Oncology Shareholders To Receive $2.035 Per Share As XOMA Royalty Acquisition; Set To Close In Early December 2025
Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), XRA 5 Corp. ("Sub") and Mural
11-26 22:03
Mural Oncology Shareholders Approve Takeover Of XOMA Royalty's XRA 5 Unit
Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. ("Sub"), a wholly owned subsidiary of XOMA
10-25 04:27
XOMA and LAVA Therapeutics Announce Amendment To Purchase Agreement; LAVA Shareholders Who Tender Their Shares Will Now Receive An Initial Cash Amount Per Share Of $1.04; Amendment To Agreement With LAVA Includes Updated CVR Terms For Tender Offer
- Amendment includes finalized cash amount and updated CVR terms for tender offer- LAVA announces new date for extraordinary general meeting of shareholdersEMERYVILLE, Calif. and UTRECHT, The Netherlands and
10-17 23:48
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
XOMA Royalty and LAVA Therapeutics have amended their share purchase agreement. Under the amendment, LAVA shareholders tendering shares will receive $1.04 per share and a CVR entitling them to 75% of net proceeds from partnered assets and up to $0.23 per CVR based on potential liabilities. The minimum net-cash closing condition was reduced to $24.5 million. The offer expiration was extended to November 12, 2025, and LAVA shareholders supporting t...
10-17 15:45
ESSA Announces Completion of Arrangement with XenoTherapeutics
SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherap...
10-09 19:00
